Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
Open Access
- 1 June 2015
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 11, 283-295
Abstract
Heart failure remains a major concern across the globe as life expectancies and delivery of health care continue to improve. There has been a dearth of new developments in heart failure therapies in the last decade until last year, with the release of the results from the PARADIGM-HF Trial heralding the arrival of a promising new class of drug, ie, the angiotensin receptor-neprilysin inhibitor. In this review, we discuss the evolution of our incremental understanding of the neurohormonal mechanisms involved in the pathophysiology of heart failure, which has led to our success in modulating its various pathways. We start by examining the renin-angiotensin-aldosterone system, followed by the challenges of modulating the natriuretic peptide system. We then delve deeper into the pharmacology and mechanisms by which angiotensin receptor-neprilysin inhibitors achieve their significant cardiovascular benefits. Finally, we also consider the potential application of this new class of drug in other areas, such as heart failure with preserved ejection fraction, hypertension, patients with renal impairment, and following myocardial infarction.Keywords
This publication has 106 references indexed in Scilit:
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- Subcutaneous B-Type Natriuretic Peptide for Treatment of Heart FailureJACC, 2012
- Novel Protein Therapeutics for Systolic Heart FailureJACC, 2012
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection FractionJACC, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- HFSA 2010 Comprehensive Heart Failure Practice GuidelineJournal of Cardiac Failure, 2010
- Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NPJACC, 2008
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated AngioedemaHypertension, 2008
- Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidneyProceedings of the National Academy of Sciences, 2006